The Fort Worth Press - eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today

USD -
AED 3.672505
AFN 64.49673
ALL 82.158918
AMD 358.939509
ANG 1.790403
AOA 916.999919
ARS 1564.860712
AUD 1.50025
AWG 1.8
AZN 1.700353
BAM 1.784033
BBD 2.019539
BDT 124.712665
BGN 1.77347
BHD 0.378367
BIF 3011.780588
BMD 1
BND 1.292991
BOB 11.787135
BRL 5.929501
BSD 1.002654
BTN 93.493996
BWP 14.163223
BYN 2.998481
BYR 19600
BZD 2.01662
CAD 1.43229
CDF 2280.000149
CHF 0.842945
CLF 0.025791
CLP 1015.079814
CNY 6.66665
CNH 6.67819
COP 3430.58
CRC 448.877578
CUC 1
CUP 24.064252
CVE 100.580597
CZK 22.29135
DJF 178.556769
DKK 6.81587
DOP 60.358117
DZD 137.168807
EGP 53.808499
ERN 15
ETB 164.575067
EUR 0.91186
FJD 2.292598
FKP 0.762556
GBP 0.763145
GEL 2.594977
GGP 0.762556
GHS 11.787081
GIP 0.762556
GMD 73.999939
GNF 8888.99024
GTQ 7.66589
GYD 209.71832
HKD 7.839502
HNL 26.953635
HRK 6.831965
HTG 131.457369
HUF 339.622503
IDR 18294.55
ILS 3.33015
IMP 0.762556
INR 92.722249
IQD 1520.092309
IRR 1937314.502631
ISK 125.109553
JEP 0.762556
JMD 158.691934
JOD 0.70896
JPY 158.9995
KES 130.059924
KGS 87.450193
KHR 4080.068959
KMF 448.999551
KPW 900.00035
KRW 1336.301234
KWD 0.31158
KYD 0.835644
KZT 451.435765
LAK 22592.768271
LBP 89796.128726
LKR 333.755975
LRD 168.449186
LSL 17.274601
LTL 2.95274
LVL 0.60489
LYD 6.489159
MAD 9.971905
MDL 18.399496
MGA 4527.086811
MKD 56.124496
MMK 2099.807194
MNT 3607.161117
MOP 8.102142
MRU 40.900654
MUR 46.780059
MVR 15.410223
MWK 1738.682283
MXN 19.082765
MYR 4.113699
MZN 63.91013
NAD 17.27405
NGN 1352.490221
NIO 36.896835
NOK 9.782355
NPR 149.590893
NZD 1.818601
OMR 0.384487
PAB 1.002755
PEN 3.42148
PGK 4.510668
PHP 63.881067
PKR 277.171369
PLN 4.05793
PYG 6286.657727
QAR 3.645038
RON 4.880398
RSD 107.266023
RUB 82.02575
RWF 1484.005145
SAR 3.751725
SBD 8.130619
SCR 13.848637
SDG 601.511051
SEK 10.202805
SGD 1.290255
SHP 0.760572
SLE 22.797529
SLL 20969.503664
SOS 573.031402
SRD 37.359778
STD 20697.981008
STN 22.348407
SVC 8.773306
SYP 13002.000337
SZL 17.270065
THB 33.939468
TJS 9.224798
TMT 3.51
TND 3.038261
TOP 2.40776
TRY 50.5779
TTD 6.803701
TWD 32.985978
TZS 2669.182985
UAH 45.169709
UGX 4246.158618
UYU 40.700724
UZS 12012.442077
VES 917.61775
VND 25793
VUV 121.154187
WST 2.823282
XAF 598.14091
XAG 0.023513
XAU 0.000279096509
XCD 2.70255
XCG 1.807054
XDR 0.707052
XOF 598.14091
XPF 108.786077
YER 236.550191
ZAR 17.48671
ZMK 9001.191204
ZMW 20.605862
ZWL 321.999592
SSP 5782.645223
MXV 2.139117
  • RIO

    -0.3300

    97.04

    -0.34%

  • CMSC

    -0.0400

    20.67

    -0.19%

  • RELX

    0.0000

    33.41

    0%

  • RBGPF

    0.0000

    67.95

    0%

  • BCE

    -0.0700

    21.99

    -0.32%

  • BCC

    -0.0300

    75.66

    -0.04%

  • GSK

    0.8600

    51.08

    +1.68%

  • JRI

    -0.0300

    11.52

    -0.26%

  • NGG

    -0.1200

    76.68

    -0.16%

  • CMSD

    0.0900

    20.54

    +0.44%

  • BTI

    -0.0800

    55.75

    -0.14%

  • AZN

    2.0200

    168.1

    +1.2%

  • BP

    -1.4200

    43.16

    -3.29%

  • RYCEF

    0.4600

    19.7

    +2.34%

  • VOD

    0.0700

    17.02

    +0.41%

eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today
eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today

eXoZymes Reports Third Quarter 2026 Results and Provides Business Update at 5PM ET Today

LOS ANGELES, CA / ACCESS Newswire / November 19, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - will host an investor webinar at 5:00 PM Eastern Time to discuss results for the third quarter ended September 30, 2026, and provide an update on recent business developments.

Text size:

Michael Heltzen, CEO of eXoZymes, states, "We're entering an exciting new phase for eXoZymes as we advance our lead product toward commercial manufacturing while expanding our pipeline of high-value molecules. Our progress with Curia and the advancement of additional product candidates demonstrate how we intend to turn our technology into a repeatable engine for commercial opportunities. We believe our ability to move rapidly from discovery toward scalable production is what sets our platform apart."

Third quarter highlights

  • Commercial manufacturing preparations underway with Curia: In September, eXoZymes selected Curia as its commercial-scale manufacturing partner for NCT, the rare natural molecule behind its lead supplement brand, Tyferyn. Technology transfer began in the fourth quarter of 2026, with the collaboration intended to support larger-scale manufacturing in 2027, representing an important step toward commercial readiness.
  • Tyferyn introduced as the brand for human use: eXoZymes introduced Tyferyn as the new brand name for its lead nutraceutical ingredient focused on human wellness applications. The rebranding establishes a distinctive, consumer-friendly identity as the Company advances preparations for commercialization.
  • Product pipeline expands: eXoZymes has advanced two additional supplement candidates through proof of concept, demonstrating the broader potential of its cell-free biomanufacturing platform. Product SAPPHIRE, targeting joint comfort, has begun scale-up activities, while Product AMETHYST, targeting mental stress, focus and energy, has also completed proof of concept. The programs support the Company's strategy of building a diversified portfolio of high-value products using its shared enzyme technology and development capabilities.
  • Operational and financial update: Operating expenses for the third quarter of 2026 were $3.05 million, compared with $2.52 million for the same period in 2025. Net loss was $2.24 million for the quarter and $7.49 million for the nine months ended September 30, 2026. Net loss for the quarter includes a $0.77 million non-cash gain from the change in fair value of warrant liabilities. The Company ended the quarter with $3.26 million in cash and cash equivalents, which the Company expects will support operations through the beginning of 2027.

Investors and interested parties can access the live webinar through eXoZymes' investor relations website at:
https://video.exozymes.com/exoz-investor-update-3q26-nov-19

Michael Heltzen, CEO of eXoZymes, will lead the call and be joined by select members of the management team to review recent developments and ongoing initiatives. A recording and transcript of the conference call will also be made publicly available following the event.

About eXoZymes
Founded in 2019, eXoZymes is pioneering a cell-free biomanufacturing platform that uses AI-enhanced enzymes - called exozymes - to make valuable natural products and new analogs outside living cells. The company's platform is designed to replace inefficient extraction and petrochemical processes with a scalable way to produce high-value molecules for nutraceutical and pharmaceutical markets.

eXoZymes is building a portfolio of biosolutions across NCT - now Tyferyn for human use - cannabinoid analogs, santalene, and other high-value natural product molecules, with potential commercialization paths that include partnerships, licensing and joint ventures. Learn more at exozymes.com

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Comms & IR
(858) 319-7135
[email protected]
LinkedIn | X | YouTube

SOURCE: eXoZymes



View the original press release on ACCESS Newswire

H.M.Hernandez--TFWP